Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)

Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)

The development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly changed the approach to tumor treatment in the last few years. The PD1 blocker nivolumab in major registered clinical trials improved overal...

Full description

Bibliographic Details
Main Authors: L. Yu. Vladimirova, A. Eh. Storozhakova, I. L. Popova, S. N. Kabanov, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, K. A. Novoselova, A. A. Lyanova, L. A. Ryadinskaya, V. S. Myagkova, F. V. Alieva, E. A. Kalabanova, Ya. V. Svetitskaya, N. Yu. Samaneva, A. V. Tishina
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-08-01
Series:Медицинский совет
Subjects:
immune checkpoint inhibitors
nivolumab
metastatic melanoma
brain metastases
immune-mediated toxicity
vitiligo
Online Access:https://www.med-sovet.pro/jour/article/view/6249

Similar Items

Similar Items